Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases

被引：135

作者：

Chun, Yun Shin ^{[1
]}

Laurent, Alexis ^{[3
]}

Maru, Dipen ^{[2
]}

Vauthey, Jean Nicolas ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA

[3] Univ Paris 12, Hop Henri Mondor, AP HP, Serv Chirurg Viscerale & Digest, F-94010 Creteil, France

来源：

LANCET ONCOLOGY | 2009年 / 10卷 / 03期

关键词：

OXALIPLATIN-BASED CHEMOTHERAPY; SINUSOIDAL OBSTRUCTION SYNDROME; HEPATIC VENOOCCLUSIVE DISEASE; STEM-CELL TRANSPLANTATION; ENDOTHELIAL GROWTH-FACTOR; PORTAL-VEIN EMBOLIZATION; NONALCOHOLIC STEATOHEPATITIS; PREOPERATIVE CHEMOTHERAPY; MAJOR HEPATECTOMY; PERIOPERATIVE CHEMOTHERAPY;

D O I：

10.1016/S1470-2045(09)70064-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Effective systemic drugs are increasingly used to treat patients with colorectal liver metastases. Recent trials have shown that chemotherapy can reduce the size of metastases that are unresectable rendering them resectable, and decrease postoperative recurrence rates in patients with initially resectable tumours. The increasing use of chemotherapy for colorectal liver metastases has raised awareness of the potential hepatotoxicities induced by systemic drugs and the effects of these drugs on outcome after hepatic resection. In this Review, we outline the rationale for the use of perioperative chemotherapy for colorectal liver metastases, associations between specific agents and patterns of liver injury, and strategies to treat patients with suspected or known chemotherapy-associated hepatotoxicity.

引用

页码：278 / 286

页数：9

共 66 条

[21] Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases [J].

Fernandez, FG ;

Ritter, J ;

Goodwin, JW ;

Linehan, DC ;

Hawkins, WG ;

Strasberg, SM .

JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2005, 200 (06) :845-853

[22] Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats [J].

Fernandez, Mercedes ;

Mejias, Marc ;

Garcia-Pras, Ester ;

Mendez, Raul ;

Garcia-Pagan, Juan Carlos ;

Bosch, Jaime .

HEPATOLOGY, 2007, 46 (04) :1208-1217

[23] The irinotecan/5-fluorouracil combination induces apoptosis and enhances manganese superoxide dismutase activity in HT-29 human colon carcinoma cells [J].

Grivicich, I ;

Regner, A ;

da Rocha, AB ;

Kayser, GB ;

Schunemann, DP ;

Grass, LB ;

Alveas, PAG ;

Henriques, JAP ;

Schwartsmann, G .

CHEMOTHERAPY, 2005, 51 (2-3) :93-102

[24] Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer [J].

Gruenberger, Brigit ;

Tamandl, Dietmar ;

Schueller, Johannes ;

Scheithauer, Werner ;

Zielinski, Christoph ;

Herbst, Friedrich ;

Gruenberger, Thomas .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (11) :1830-1835

[25] GLUTAMINE PRESERVES LIVER GLUTATHIONE AFTER LETHAL HEPATIC-INJURY [J].

HONG, RW ;

ROUNDS, JD ;

HELTON, WS ;

ROBINSON, MK ;

WILMORE, DW .

ANNALS OF SURGERY, 1992, 215 (02) :114-119

[26] THE EFFECT OF CISPLATIN AND TRANSPLATIN ON THE CONFORMATION AND ASSOCIATION OF F-ACTIN [J].

HUI, ZH ;

FEN, LJ ;

KUI, W .

CELL BIOLOGY INTERNATIONAL, 1995, 19 (06) :491-497

[27] Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].

Hurwitz, H ;

Fehrenbacher, L ;

Novotny, W ;

Cartwright, T ;

Hainsworth, J ;

Heim, W ;

Berlin, J ;

Baron, A ;

Griffing, S ;

Holmgren, E ;

Ferrara, N ;

Fyfe, G ;

Rogers, B ;

Ross, R ;

Kabbinavar, F .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342

[28] Vascular endothelial growth factor (VEGF) is one of the cytokines causative and predictive of hepatic veno-occlusive disease (VOD) in stem cell transplantation [J].

Iguchi, A ;

Kobayashi, R ;

Yoshida, M ;

Kobayashi, K ;

Matsuo, K ;

Kitajima, I ;

Maruyama, I .

BONE MARROW TRANSPLANTATION, 2001, 27 (11) :1173-1180

[29] UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity [J].

Iyer L. ;

Das S. ;

Janisch L. ;

Wen M. ;

Ramírez J. ;

Karrison T. ;

Fleming G.F. ;

Vokes E.E. ;

Schilsky R.L. ;

Ratain M.J. .

The Pharmacogenomics Journal, 2002, 2 (1) :43-47

[30]

JULIE C, 2007, ASCO 2007 GASTR CANC

← 1 2 3 4 5 6 7 →